CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06991114
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:45.101530+00:00
Published At: 2025-12-24T00:00:00+00:00
Record Updated At: 2025-12-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Refractory Rheumatoid Arthritis (RA)", "Idiopathic Inflammatory Myopathies (IIMs)", "Systemic Sclerosis (SSc)", "Rheumatoid Arthritis (RA", "IIM", "Myositis", "Scleroderma", "Sjogren Syndrome", "Sjogrens Disease"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-24"
protocolSection.identificationModule.nctId: "NCT06991114"
protocolSection.identificationModule.officialTitle: "An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK\u00ae, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.